DICE Therapeutics, Inc. Common Stock
DICE
DICE was delisted on the 8th of August, 2023.
160 hedge funds and large institutions have $2.11B invested in DICE Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 77 funds opening new positions, 39 increasing their positions, 33 reducing their positions, and 32 closing their positions.
141% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 32
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
42% more capital invested
Capital invested by funds: $1.49B → $2.11B (+$620M)
39% more funds holding
Funds holding: 115 → 160 (+45)
18% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 33
52% less call options, than puts
Call options by funds: $25.1M | Put options by funds: $52.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$73.2M |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$40M |
| 3 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$37.3M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$37.2M |
| 5 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
+$33.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$119M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$110M |
| 3 |
NV
Northpond Ventures
Bethesda,
Maryland
|
-$94.3M |
| 4 |
SCV
Sands Capital Ventures
Arlington,
Virginia
|
-$78.8M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$60.5M |
DICE Hedge Fund Activity: Q2 2023 in Review
160 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in DICE Therapeutics, Inc. Common Stock (DICE) for Q2 2023, worth a combined $2.11B — up 42% from $1.49B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new DICE positions and 32 closed out — a net gain of 45 holders — while 39 added to existing stakes and 33 trimmed.
The largest buyer was Alpine Associates Management, opening a new position worth an estimated $73.2M. The largest seller was Fidelity Investments, cutting an estimated $119M.
- 160 institutional investors held DICE Therapeutics, Inc. Common Stock (DICE) as of Q2 2023, up from 115 in Q1 2023.
- Funds reported $2.11B of DICE Therapeutics, Inc. Common Stock stock for Q2 2023, up 42% quarter-over-quarter.
- 77 funds opened new DICE Therapeutics, Inc. Common Stock positions in Q2 2023 and 32 closed out, a net change of +45 holders.
- The largest DICE Therapeutics, Inc. Common Stock buyer in Q2 2023 was Alpine Associates Management, an estimated $73.2M added.
- The largest DICE Therapeutics, Inc. Common Stock seller in Q2 2023 was Fidelity Investments, an estimated $119M sold.
Based on aggregated 13F filings for Q2 2023.